After 8 weeks of treatment, body fat analysis and bone mineral density testing of mice in each group. by Xueqin lu (22250795)

Subjects:

Office characteristics and RW adoption. by Yasuhiko Deguchi (3167955)

Subjects:

Newly occurring LTSA-MD cases in workers for over a month. by Yasuhiko Deguchi (3167955)

Subjects:

Difference in the number of LTSA between FY 2020 and FY 2019. by Yasuhiko Deguchi (3167955)

Subjects:

Pharmacological efficacy of Kylo-0603 in MASH mouse models (F2 ~ 3). by Xueqin lu (22250795)

Subjects:

The Chol and TG content in liver homogenates of the mice in each group after 2 and 10 weeks of drug intervention. by Xueqin lu (22250795)

Subjects:

Plasma cholesterol and LDL-C levels. by Xueqin lu (22250795)

Subjects:

The Laboratory Animal Flow Diagram. by Xueqin lu (22250795)

Subjects:

¹³C NMR spectra for Kylo-0603. by Xueqin lu (22250795)

Subjects:

The structures of T3 and Kylo-0603. by Xueqin lu (22250795)

Subjects:

Synthesis process of Kylo-0603. by Xueqin lu (22250795)

Subjects:

ESI-HRMS spectra for Kylo-0603. by Xueqin lu (22250795)

Subjects:

Effects of Kylo-0603 on body weight, organ weight, and body fat content. by Xueqin lu (22250795)

Subjects:

Flow diagram illustrating the sequence of procedures executed during one time step defined as tick, each of which represents one week. by Alexandra M. Campbell (3284094)

Subjects:

Fig 7 - by Keith Fraser (1868587)

Subjects:

Fig 6 - by Keith Fraser (1868587)

Subjects:

Three-dimensional topography of concrete joints. by Zhezhe Zhang (19704587)

Subjects:

Test results under the UNLCSL path. by Zhezhe Zhang (19704587)

Subjects:

Test scheme. by Zhezhe Zhang (19704587)

Subjects:

Preparation process of concrete joint specimens. by Zhezhe Zhang (19704587)

Subjects: